EU panel recommends Bayer, GSK drugs

The EU's drug panel, the Committee for Human Medicinal Products, is meeting this week, separating the wheat from the chaff in a new batch of applications for approval. Among the existing drugs recommended for new indications: Nexavar, the Bayer/Onyx Pharmaceuticals kidney-cancer drug, for use in liver cancer; and several GlaxoSmithKline anti-HIV drugs, which won approval for use in children.

The panel also recommended absolution for Roche's HIV drug Viracept, which was pulled from the market when some batches were contaminated. The CHMP said it was satisfied with the actions Roche took to fix the problem.

- see the statement from the EMEA detailing the CHMP's current decisions
- read this piece in Forbes about Viracept
- read this article from Trading Markets on Nexavar

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.